[HTML][HTML] Shorter infusion time of ocrelizumab: results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple …
Background: Ocrelizumab is an approved intravenously administered anti-CD20 antibody
for multiple sclerosis (MS). Shortening the 600 mg infusion to 2 hours reduces the total site …
for multiple sclerosis (MS). Shortening the 600 mg infusion to 2 hours reduces the total site …
[HTML][HTML] Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis
Background Ocrelizumab is an approved MS treatment administered as two 300-mg
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours …
intravenous infusions 2 weeks apart (Dose 1), each lasting approximately 2.5 hours …
Ocrelizumab shorter infusion: primary results from the ENSEMBLE PLUS substudy in patients with MS
HP Hartung - Neurology: Neuroimmunology & Neuroinflammation, 2020 - AAN Enterprises
Objective To assess the safety of ocrelizumab (OCR) shorter duration infusion in patients
with MS. Methods ENSEMBLE PLUS is a randomized, double-blind substudy to the single …
with MS. Methods ENSEMBLE PLUS is a randomized, double-blind substudy to the single …
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and …
Background Ocrelizumab is an infusible humanized monoclonal antibody that selectively
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …
depletes CD20+ B cells. Infusion-related reactions (IRRs) were summarized from the …
Ocrelizumab: a review in multiple sclerosis
YN Lamb - Drugs, 2022 - Springer
Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …
Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population
H Coban, S Germaine, I Dimaandal, N Haberli… - Multiple Sclerosis and …, 2021 - Elsevier
Background Ocrelizumab (OCR) is a humanized monoclonal antibody directed against
CD20 positive B-lymphocytes. It was approved for use in 2017 by the US Food and Drug …
CD20 positive B-lymphocytes. It was approved for use in 2017 by the US Food and Drug …
Real world application of ocrelizumab in multiple sclerosis: Single-center experience of 128 patients
V Prockl, FT Nickel, KS Utz, K Fröhlich… - Journal of the …, 2020 - Elsevier
Background Pivotal trials showed good clinical efficiency of the monoclonal antibody
ocrelizumab while being well tolerated and manageable in multiple sclerosis (MS) …
ocrelizumab while being well tolerated and manageable in multiple sclerosis (MS) …
Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: final results from the PRO-MSACTIVE study
E Manchon, D Laplaud, S Vukusic, P Labauge… - Multiple Sclerosis and …, 2022 - Elsevier
Background Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has been
approved in Europe for the treatment of adult patients with active relapsing multiple sclerosis …
approved in Europe for the treatment of adult patients with active relapsing multiple sclerosis …
Ocrelizumab: a review in multiple sclerosis
YY Syed - CNS drugs, 2018 - Springer
Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …
Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension
Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …
modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase …